A biologics license application has been filed with the FDA for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.
Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.
Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.
The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.
Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.
The EMA’s CHMP has recommended the approval of brentuximab vedotin plus ECADD for newly diagnosed, stage IIB/III/IV Hodgkin lymphoma.
China’s NMPA has approved the sNDA for toripalimab as a first-line treatment for patients with unresectable or metastatic melanoma.
Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.
Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.
